Inventor · disambiguated record
Simon Barry
Also filed as: BARRY SIMON · BARRY SIMON T · BARRY SIMON THOMAS
6 granted patents·12 pending applications·41 citations·filing 2001–2022
81Inventor score
Files withMEDIMMUNE LTD5ASTRAZENECA AB2EBERLEIN CATHERINE ANNE2RINKENBERGER JULIE2SMITHKLINE BEECHAM CORP2
Top patents by PatentIndex Score
18 records- 0185US8398975B2Antibodies directed to αVβ6 and uses thereofRINKENBERGER JULIE·Filed 2010·Granted Mar 19, 2013·15 cites·9 claims
- 0285US8119130B2Targeted binding agents directed to KDR and uses thereof—035BARRY SIMON THOMAS·Filed 2008·Granted Feb 21, 2012·14 cites·4 claims
- 0377US7662633B2Method of screening for inhibitors of osteopontinGLAXOSMITHKLINE LLC·Filed 2006·Granted Feb 16, 2010·7 cites·10 claims
- 0470US8894998B2Antibodies directed to αVβ6 and uses thereofMEDIMMUNE LTD·Filed 2013·Granted Nov 25, 2014·1 cites·8 claims
- 0561US7504232B2Method of screening for inhibitors of osteopontinSMITHKLINE BEECHAM CORP·Filed 2001·Granted Mar 17, 2009·3 cites·14 claims
- 0659US2015166663A1Antibodies Directed To Alpha V Beta 6 And Uses ThereofMEDIMMUNE LTD·Filed 2014·Application pending·0 cites
- 0758US2012107324A1TARGETED BINDING AGENTS DIRECTED TO a5ß1 AND USES THEREOFEBERLEIN CATHERINE ANNE·Filed 2009·Application pending·0 cites
- 0857US2025381190A1Therapeutic combinations of capivasertib and venetoclaxASTRAZENECA AB·Filed 2022·Application pending·0 cites
- 0956US7037666B2Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin αvβ3 and medical use thereofSMITHKLINE BEECHAM CORP·Filed 2001·Granted May 2, 2006·1 cites·6 claims
- 1055US2008057063A1Antibodies Directed to AlphaVBeta6 and Uses ThereofRINKENBERGER JULIE·Filed 2007·Application pending·0 cites
- 1152US2016319032A1Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancerMEDIMMUNE LTD·Filed 2014·Application pending·0 cites
- 1251US2019389967A1Method of treating and diagnosing alpha-v-beta-6 overexpressing cancerMEDIMMUNE LTD·Filed 2018·Application pending·0 cites
- 1351US2010196398A1Targeted binding agents directed to cd105 and uses thereofMEDIMMUNE LLC·Filed 2009·Application pending·0 cites
- 1450US2012114667A1TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOFEBERLEIN CATHERINE ANNE·Filed 2009·Application pending·0 cites
- 1542US2009137601A1L-Phenylalanine DerivativesASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 1636US2021322415A1Methods comprising fixed intermittent dosing of cediranibASTRAZENE CA AB·Filed 2017·Application pending·0 cites
- 1734US2017320954A1Therapeutic combinations and methods for treating neoplasiaMEDIMMUNE LTD·Filed 2015·Application pending·0 cites
- 1833US2005063969A1AssayFiled 2002·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →